|
|
Post by centralcoastinvestor on Aug 29, 2019 8:15:12 GMT -5
|
|
|
|
Post by centralcoastinvestor on Aug 29, 2019 8:36:16 GMT -5
When I read the study at first, I just assumed because it talked about inhaled insulin, it was about Afrezza. Then I realized it was about Exubera. I haven’t seen Exubera mentioned in a long while. What does this mean? I think it means that inhaled insulin is beginning to take off and that anything inhaled is worth a second look. Who knows.
|
|
|
|
Post by uvula on Aug 29, 2019 8:45:02 GMT -5
I wish I had your optimistic outlook. Most likely it just took an unusually long time to get the study published.
|
|
|
|
Post by kite on Aug 29, 2019 8:47:38 GMT -5
When I read the study at first, I just assumed because it talked about inhaled insulin, it was about Afrezza. Then I realized it was about Exubera. I haven’t seen Exubera mentioned in a long while. What does this mean? I think it means that inhaled insulin is beginning to take off and that anything inhaled is worth a second look. Who knows. I really dont want to see any other inhaled insulin on the market for a while except for Afrezza |
|
|
|
Post by agedhippie on Aug 29, 2019 8:48:42 GMT -5
When I read the study at first, I just assumed because it talked about inhaled insulin, it was about Afrezza. Then I realized it was about Exubera. I haven’t seen Exubera mentioned in a long while. What does this mean? I think it means that inhaled insulin is beginning to take off and that anything inhaled is worth a second look. Who knows. What it does is put "Afrezza", "inhaled" and "Exubera" together. I don't feel that association with Exubera, a failed inhaled insulin, is good for Afrezza. |
|
|
|
Post by lifebreath on Aug 29, 2019 9:09:34 GMT -5
It’s another tactic to harm the reputation of Afrezza. It makes no sense to publish a paper evaluating exubera. The purpose is so people will associate all inhaled insulin into one category together. The authors were likely paid to write this
|
|
|
|
Post by wsulylecoug on Aug 29, 2019 9:14:56 GMT -5
"Received: 7 May 2019; Accepted: 22 August 2019; Published: 29 August 2019"
What is going on? So confused...
|
|
|
|
Post by Clement on Aug 29, 2019 9:17:12 GMT -5
mdpi --- Multidisciplinary Digital Publishing Institute
Look it up on Wikipedia. It's been involved in some controversies.
|
|
|
|
Post by letitride on Aug 29, 2019 9:22:58 GMT -5
Real obvious why it was done in light of our most recent marketing campaign
|
|
|
|
Post by letitride on Aug 29, 2019 9:29:01 GMT -5
It might be a great time to publish a paper comparing the 2 and running it simultaneously in the same places.
|
|
|
|
Post by joeypotsandpans on Aug 29, 2019 9:30:37 GMT -5
Real obvious why it was done in light of our most recent marketing campaign Look at Pfizer trying to capitalize on MNKD's back  ....some morning humor, however this is interesting: Conflicts of Interest: Rucha J. Mehta, Andrea Ricotti, Bogdana Balas, and Devjit Tripathy declare they have no conflict of interest for this article. Amalia Gastaldelli is consultant for Eli-Lilly, Menarini, Gilead, Inventiva, and Genentech. Ralph A. DeFronzo: Advisory Board: Astra Zeneca, Novo Nordisk, Janssen, Boehringer-Ingelheim, Intarcia, Elcelyx; Research Support: Boehringer-Ingelheim, Astra Zeneca, Janssen, Merck, Speaker’s Bureau: Novo-Nordisk, Astra Zeneca |
|
|
|
Post by Clement on Aug 29, 2019 9:32:54 GMT -5
Info about the first author according to edmo.in:
"Dr. Rucha J Mehta is an experienced Endocrinologist in Ahmedabad, practising at the EDMO Clinic located opposite the Karnavati Club. She is also associated as Consultant Endocrinologist at the BJ Medical College and Civil Hospital (Ahmedabad), Muljibhai Patel Urological Hospital (Nadiad), Apollo Hospitals (Gandhinagar), Asian Bariatrics (Ahmedabad), and Global Hospitals (Mumbai).
After completing her undergraduate medical studies (MBBS) at Seth GS Medical College and KEM Hospital in Mumbai in 1999, Dr. Rucha Mehta was designated as Government Medical Officer of the Maharashtra State Government, before moving to the United States in 2000. Her first assignment there was as Clinical Research Coordinator at Stanford and VA Hospitals, Palo Alto, California until 2001. From June 2001 to June 2004 she undertook an Internship and Residency in Internal Medicine at Christ Medical Center, University of Illinois, Chicago. She later completed a two-year Fellowship in Endocrinology, Diabetes and Metabolism at the University of Texas Health Sciences Center, San Antonio (UTHSCSA). She continued there as Postdoctoral Fellow Diabetes from October 2007 to June 2008.
Dr. Rucha Mehta held the title of Assistant Professor at the UIC/Advocate Christ Medical Center from 2004 to 2005. Subsequently, from 2008 to 2012, she had associations as Physician with the Audie L Murphy VA Hospital, San Antonio, and as clinical faculty at the University of California, and VA Hospitals, Greater Los Angeles. During this period she also served as Director of Research at Western Diabetes Institute, and as Assistant Professor, Department of Internal Medicine, and Division of Endocrinology, Diabetes and Metabolism of the College of Osteopathic Medicine, Pacific Western University of Health Sciences, California. Dr. Mehta returned to practice in India in October 2012."
This info places her at the UT Health Sciences Center between 2004 and 2008. My opinion is that this Mehta is the one listed as first author. The article, dated August 29, 2019, indicates that she is at University of Texas Health Sciences Center.
|
|
|
|
Post by uvula on Aug 29, 2019 9:41:16 GMT -5
Is exubera still being sold outside the usa?
|
|
|
|
Post by lifebreath on Aug 29, 2019 9:42:22 GMT -5
mdpi --- Multidisciplinary Digital Publishing Institute Look it up on Wikipedia. It's been involved in some controversies. It’s a National Enquirer type publication. I found one article referring to them as a fake journal |
|
|
|
Post by letitride on Aug 29, 2019 9:51:34 GMT -5
New marketing campaign this aint your daddy exubera
|
|
....some morning humor, however this is interesting: